Abaloparatide-Zoledronate combination protects against 4-vinylcyclohexene diepoxide-induced postmenopausal osteoporosis in mice: an osteoanabolic-antiresorptive approach.

Ara T, Iqbal Z, Jain S, Sheikh AA, Vohora D

Naunyn-Schmiedeberg's archives of pharmacology24 Jan 2026

PMID41579168DOI10.1007/s00210-026-04984-9PepBankPUB-41579168

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, abaloparatide alone partially reversed VCD-induced changes in bone microarchitecture.
In plain wordsIn mice, abaloparatide alone partially reversed bone structure changes caused by VCD.
Peptide
Abaloparatide (Tymlos)
Outcome
Direction not reportedBone microarchitecture with abaloparatide alone
Study
mousen: not reported in source
VCD-induced postmenopausal osteoporosis in female Swiss albino mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg/d · subcutaneous · 30 daysAs given in this study (mouse).
Source sentences
Summary
Treatment with abaloparatide and zoledronate combination for 30 days reversed VCD-induced alterations of BV/TV, BMD, Tb.N, and Tb.Sp, while the individual treatments were only partially effective.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the impact of abaloparatide (20 µg/kg/d; s.c.), an osteoanabolic drug with an antiresorptive drug zoledronate (125 µg/kg i.v.) twice weekly for a month against 4-vinylcyclohexene diepoxide (VCD)-induced postmenopausal osteoporosis in mice.
Summary · context
Female Swiss albino mice were made ovotoxic by treatment with VCD (160 mg/kg/d) for 15 days to mimic a postmenopausal state, confirmed by primordial follicle destruction in histopathological assessment.
Report a problemFND-4157916802
02AnimalAnimal study (in vivo)Efficacy outcome
In mice, abaloparatide alone reversed VCD-induced alterations in P1NP, CTX-1, and RANKL.
In plain wordsIn mice, abaloparatide alone reversed changes in three bone markers caused by VCD.
Peptide
Abaloparatide (Tymlos)
Outcome
Direction not reportedBone turnover markers with abaloparatide alone
Study
mousen: not reported in source
VCD-induced postmenopausal osteoporosis in female Swiss albino mice
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 µg/kg/d · subcutaneousAs given in this study (mouse).
Source sentences
Summary
The abaloparatide individually and in combination reversed the VCD-induced alterations in P1NP, CTX-1, and RANKL.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the impact of abaloparatide (20 µg/kg/d; s.c.), an osteoanabolic drug with an antiresorptive drug zoledronate (125 µg/kg i.v.) twice weekly for a month against 4-vinylcyclohexene diepoxide (VCD)-induced postmenopausal osteoporosis in mice.
Summary · context
Female Swiss albino mice were made ovotoxic by treatment with VCD (160 mg/kg/d) for 15 days to mimic a postmenopausal state, confirmed by primordial follicle destruction in histopathological assessment.
Report a problemFND-4157916803

Studies that did not test the peptide alone3

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

03AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In mice, abaloparatide plus zoledronate reversed VCD-induced changes in BV/TV, BMD, Tb.N, and Tb.Sp, while individual treatments were partially effective.
In plain wordsIn mice, abaloparatide plus zoledronate reversed bone structure changes, while each drug alone had partial effects.
Peptide
Abaloparatide (Tymlos)
Outcome
Direction not reportedBone microarchitecture with combination
Study
mousen: not reported in source
VCD-induced postmenopausal osteoporosis in female Swiss albino mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Treatment with abaloparatide and zoledronate combination for 30 days reversed VCD-induced alterations of BV/TV, BMD, Tb.N, and Tb.Sp, while the individual treatments were only partially effective.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the impact of abaloparatide (20 µg/kg/d; s.c.), an osteoanabolic drug with an antiresorptive drug zoledronate (125 µg/kg i.v.) twice weekly for a month against 4-vinylcyclohexene diepoxide (VCD)-induced postmenopausal osteoporosis in mice.
Summary · context
Female Swiss albino mice were made ovotoxic by treatment with VCD (160 mg/kg/d) for 15 days to mimic a postmenopausal state, confirmed by primordial follicle destruction in histopathological assessment.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4157916801
04AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In mice, abaloparatide plus zoledronate reversed VCD-induced alterations in P1NP, CTX-1, and RANKL.
In plain wordsIn mice, abaloparatide plus zoledronate reversed changes in three bone markers caused by VCD.
Peptide
Abaloparatide (Tymlos)
Outcome
Direction not reportedBone turnover markers with combination
Study
mousen: not reported in source
VCD-induced postmenopausal osteoporosis in female Swiss albino mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The abaloparatide individually and in combination reversed the VCD-induced alterations in P1NP, CTX-1, and RANKL.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the impact of abaloparatide (20 µg/kg/d; s.c.), an osteoanabolic drug with an antiresorptive drug zoledronate (125 µg/kg i.v.) twice weekly for a month against 4-vinylcyclohexene diepoxide (VCD)-induced postmenopausal osteoporosis in mice.
Summary · context
Female Swiss albino mice were made ovotoxic by treatment with VCD (160 mg/kg/d) for 15 days to mimic a postmenopausal state, confirmed by primordial follicle destruction in histopathological assessment.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4157916804
05AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Efficacy outcome
In mice, abaloparatide plus zoledronate lowered the RANKL/OPG ratio.
In plain wordsIn mice, abaloparatide plus zoledronate lowered the ratio of two bone regulation markers.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseRANKL/OPG ratio with combination
Study
mousen: not reported in source
VCD-induced postmenopausal osteoporosis in female Swiss albino mice
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The combination therapy also lowered the RANKL/OPG ratio.
2 context sentences(design, population, supporting numbers)
Summary · context
This study aimed to investigate the impact of abaloparatide (20 µg/kg/d; s.c.), an osteoanabolic drug with an antiresorptive drug zoledronate (125 µg/kg i.v.) twice weekly for a month against 4-vinylcyclohexene diepoxide (VCD)-induced postmenopausal osteoporosis in mice.
Summary · context
Female Swiss albino mice were made ovotoxic by treatment with VCD (160 mg/kg/d) for 15 days to mimic a postmenopausal state, confirmed by primordial follicle destruction in histopathological assessment.
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Report a problemFND-4157916805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.